Training Reps for Formulary Committee Presentations
A formulary decision in a large health system can affect thousands of patients and represent millions in revenue. Getting your product on formulary opens access across the entire system. Failing can lock you out for months or years, until the next review cycle.
Yet many reps walk into pharmacy and therapeutics (P&T) committee presentations underprepared. They approach it like a typical HCP visit, only longer. They lead with the same clinical messaging they use in one-on-one conversations.
They are caught off guard by the questions, the format, and the level of scrutiny from a panel of clinical experts who have already reviewed the data.
P&T committee presentations are a fundamentally different selling environment. They require different preparation, different skills, and different training.
Understanding the committee
The first step is knowing who sits on the other side of the table.
P&T committees typically include hospital pharmacists, clinical specialists in the relevant therapeutic area, a medical director, nursing representatives, and sometimes administrative or financial stakeholders. The American Society of Health-System Pharmacists (ASHP) provides guidelines on committee operations that describe this multidisciplinary composition.
Each member evaluates your product through a different lens.
The clinical pharmacist scrutinises pharmacokinetic data, drug interactions, and how your product fits into existing treatment protocols. The physician specialist compares your efficacy data to their own clinical experience. The medical director considers system-wide implications: safety, staff training, formulary complexity. The finance representative examines budget impact and sustainability.
Understanding this composition shapes every aspect of your preparation, from which data you lead with to which questions you rehearse.
Leading with pharmacoeconomic data
In one-on-one HCP conversations, clinical efficacy often leads. In a P&T committee, pharmacoeconomics frequently carries equal or greater weight.
The committee needs to justify the cost of adding your product. That justification requires clear value-for-money evidence.
The Academy of Managed Care Pharmacy (AMCP) publishes the AMCP Format for Formulary Submissions, a standardised framework for evaluating drugs for formulary inclusion. Familiarise yourself with this format. Structure your presentation to address its key elements: clinical evidence, safety, pharmacoeconomic analysis, and place in therapy.
This means leading with the data the committee needs to make their decision, not the data you find most impressive.
A statistically significant improvement in a secondary endpoint may be fascinating to a researcher but irrelevant to a committee weighing budget impact against clinical benefit. Focus on primary endpoints, safety data that address risk concerns, and pharmacoeconomic analyses relevant to their health system.
Reps trained only for one-on-one conversations often struggle with this shift. They want to lead with the clinical story that excites them. The committee wants the story that answers their questions. These are not always the same.
Anticipating clinical questions
P&T committees ask hard questions. They have clinical expertise, they have read the literature, and they have likely reviewed your data before you arrive.
Common areas of questioning include:
- Trial design. Was the trial adequately powered? What was the comparator, and why? Were there issues with blinding, randomisation, or dropout rates?
- Subgroup analyses. Does the benefit hold across patient subgroups? Are there populations where the risk-benefit balance shifts unfavourably?
- Safety. What adverse events appeared? How do they compare to existing options? Have new signals emerged since approval?
- Real-world evidence. How does the product perform outside trial conditions? Are there observational or registry data?
- Place in therapy. Where does this fit relative to existing formulary options? Does it replace something or add complexity?
Reps must be prepared for all of these. "I'll get back to you" is acceptable for genuinely obscure questions, but not for predictable ones.
Every unanswered question is a reason for the committee to defer. Deferred decisions often become denials.
A realistic scenario
Consider presenting a new biologic for a moderate-to-severe inflammatory condition. The product demonstrated superior efficacy to current standard in a phase three trial, but at significantly higher cost. Two existing biologics are already on formulary.
The committee chair, a rheumatologist, opens: "Walk us through the primary endpoint data and explain why we should add a third biologic."
This is direct but fair. The rep needs to present efficacy data clearly, acknowledge existing options, and articulate which patients are underserved by current formulary options. "Our product is better" will not work. "Here is the specific patient population currently underserved, and here is the evidence our product addresses that gap" will.
The pharmacist asks: "What is the budget impact for a system our size?"
The rep must have this prepared with institution-specific figures, not generic national data. Showing you have done your homework on their system signals respect and seriousness.
A clinical pharmacologist follows: "Your trial comparator wasn't the biologic most commonly used here. How confident can we be in extrapolating?"
This requires nuance. Acknowledge the limitation honestly. Reference indirect comparisons or meta-analyses if they exist. Avoid overstating. Credibility in front of a P&T committee is built on honesty about what the data show and what they do not.
Handling challenges to your evidence
Committee members will probe weaknesses. This is their job. They are responsible for their institution's formulary, and they take it seriously.
How a rep handles challenges often matters as much as the data itself.
Acknowledge the question fully before responding. Do not become defensive. Distinguish between what the data demonstrate and what they suggest. When evidence has limitations, say so. Explain what additional data are coming. Never exceed the approved label.
Reps who handle challenges well earn respect, even when data are imperfect. Reps who dodge questions or overstate results undermine their credibility and the product's chances.
The follow-up process
Most P&T committees do not decide immediately. They review, deliberate, and may request additional information.
Provide anything requested promptly. If the committee asked for additional data, deliver it within days, not weeks. Coordinate with your medical science liaison for questions requiring deeper scientific expertise.
If approved, shift to implementation: stocking, ordering, clinical protocols, staff education. A formulary win without effective implementation wastes the opportunity.
If deferred or denied, understand specifically why. Address concerns for the next review cycle. Many successful additions happen on the second or third attempt, once initial questions have been thoroughly answered.
Why this requires dedicated training
P&T presentations cannot be trained through the same methods used for everyday HCP interactions.
The format is different: formal, panel-based, evidence-intensive. The audience is different: multidisciplinary, expert, evaluative. The stakes are different: a single decision affects system-wide access.
Reps need preparation that includes understanding committee dynamics, structuring evidence-based presentations, rehearsing responses to challenging questions, and developing composure under scrutiny.
AI roleplay tools like TrainBox can simulate P&T scenarios with multiple panel members asking different types of questions, giving reps a realistic rehearsal before the real thing.
The reps who perform best in front of committees are rarely the ones with the most clinical knowledge. They are the ones who have practised the format, anticipated the questions, and developed the confidence that comes from thorough preparation.
That confidence is visible across the table. And committees notice it.
TrainBox helps life science teams practise real conversations so they're ready when it matters.